<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955602</url>
  </required_header>
  <id_info>
    <org_study_id>CB8025-21629</org_study_id>
    <nct_id>NCT02955602</nct_id>
  </id_info>
  <brief_title>Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)</brief_title>
  <official_title>An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With a 44-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intolerance to Ursodeoxycholic Acid (UDCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to&#xD;
      evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis&#xD;
      (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:&#xD;
&#xD;
      To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 8 weeks of&#xD;
      treatment&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 12 and 26 weeks of&#xD;
      treatment&#xD;
&#xD;
      To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of&#xD;
      treatment&#xD;
&#xD;
      To evaluate the pharmacokinetics (PK) of MBX-8025&#xD;
&#xD;
      Exploratory:&#xD;
&#xD;
      To evaluate the effect of MBX-8025 on bile acids, additional markers of inflammation and&#xD;
      renal function&#xD;
&#xD;
      MBX-8025 doses of 1 mg and 15 mg may be evaluated if dose adjustment occurs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Actual">July 8, 2019</completion_date>
  <primary_completion_date type="Actual">September 7, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Alkaline Phosphatase (AP)</measure>
    <time_frame>over 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) and Treatment Emergent Adverse Events (TEAEs), ECG, biochemistry, hematology and urinalysis (NCI CTCAE Version 4.0)</measure>
    <time_frame>over 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Alkaline Phosphatase (AP)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl Transferase (GGT)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5'nucleotidase</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin - Total Bilirubin</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin - Conjugated Bilirubin</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin - Unconjugated Bilirubin</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Specific Alkaline Phosphatase (AP)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (TC)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of AP and Total Bilirubin</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
    <description>AP &lt; 1.67 × upper limit of normal (ULN)&#xD;
Total Bilirubin within normal limit&#xD;
&gt; 15% decrease in AP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Paris I</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Paris II</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Toronto I</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Toronto II</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - UK-PBC Risk Score</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5D-itch Scale</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus Visual Analog Score (VAS)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBC-40 Quality of Life (QoL)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of MBX-8025 and Metabolites</measure>
    <time_frame>(at 0, 0.5, 1, 2, 4, 6 and 24 hours for Cmax, Tmax, T1/2, AUC and trough level)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Barcelona</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>MBX-8025 (2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 2 mg capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 5 mg capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 10 mg capsule once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 2 mg Capsule</intervention_name>
    <description>Initial 8-week treatment:&#xD;
• MBX-8025 2 mg&#xD;
Extension:&#xD;
The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.&#xD;
Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.</description>
    <arm_group_label>MBX-8025 (2 mg)</arm_group_label>
    <other_name>MBX-8025</other_name>
    <other_name>seladelpar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 5 mg Capsule</intervention_name>
    <description>Initial 8-week treatment:&#xD;
• MBX-8025 5 mg&#xD;
Extension:&#xD;
Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.</description>
    <arm_group_label>MBX-8025 (5 mg)</arm_group_label>
    <other_name>MBX-8025</other_name>
    <other_name>seladelpar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 10 mg Capsule</intervention_name>
    <description>Initial 8-week treatment:&#xD;
• MBX-8025 10 mg&#xD;
Extension:&#xD;
Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.</description>
    <arm_group_label>MBX-8025 (10 mg)</arm_group_label>
    <other_name>MBX-8025</other_name>
    <other_name>seladelpar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have given written informed consent (signed and dated) and any authorizations&#xD;
             required by local law&#xD;
&#xD;
          2. 18 to 75 years old (inclusive)&#xD;
&#xD;
          3. Male or female with a diagnosis of PBC, by at least two of the following criteria:&#xD;
&#xD;
               -  History of AP above ULN for at least six months&#xD;
&#xD;
               -  Positive AMA titers (&gt;1/40 on immunofluorescence or M2 positive by enzyme linked&#xD;
                  immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies&#xD;
&#xD;
               -  Documented liver biopsy result consistent with PBC&#xD;
&#xD;
          4. On a stable and recommended dose of UDCA for the past twelve months or intolerant to&#xD;
             UDCA&#xD;
&#xD;
          5. AP ≥ 1.67 × ULN&#xD;
&#xD;
          6. Females of reproductive potential must use at least one barrier contraceptive and a&#xD;
             second effective birth control method during the study and for at least 90 days after&#xD;
             the last dose. Male subjects who are sexually active with female partners of&#xD;
             reproductive potential must use barrier contraception and their female partners must&#xD;
             use a second effective birth control method during the study and for at least 90 days&#xD;
             after the last dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A medical condition, other than PBC, that in the investigator's opinion would preclude&#xD;
             full participation in the study or confound its results (e.g., cancer on active&#xD;
             treatment)&#xD;
&#xD;
          2. AST or ALT &gt; 3 × ULN&#xD;
&#xD;
          3. Total bilirubin &gt; 2.0 mg/dL&#xD;
&#xD;
          4. Total bilirubin &gt; ULN AND albumin &lt; LLN with the exception to subjects with Gilbert's&#xD;
             Syndrome. Subjects with Gilbert's syndrome are excluded if Direct Bilirubin &gt; ULN.&#xD;
&#xD;
          5. Auto-immune hepatitis&#xD;
&#xD;
          6. Primary sclerosing cholangitis&#xD;
&#xD;
          7. Known history of alpha-1-Antitrypsin deficiency&#xD;
&#xD;
          8. Known history of chronic viral hepatitis&#xD;
&#xD;
          9. Creatine kinase above ULN&#xD;
&#xD;
         10. Serum creatinine above ULN&#xD;
&#xD;
         11. For females, pregnancy or breast-feeding&#xD;
&#xD;
         12. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months&#xD;
             preceding screening&#xD;
&#xD;
         13. Current use of fibrates or simvastatin&#xD;
&#xD;
         14. Current use of obeticholic acid&#xD;
&#xD;
         15. Use of an experimental or unapproved treatment for PBC&#xD;
&#xD;
         16. Use of experimental or unapproved immunosuppressant&#xD;
&#xD;
         17. Adverse event leading to MBX-8025 discontinuation from CymaBay's phase 2 PBC study&#xD;
             (CB8025-21528)&#xD;
&#xD;
         18. Any other condition(s) that would compromise the safety of the subject or compromise&#xD;
             the quality of the clinical study, as judged by the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute for Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Standford University Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami - Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Healthcare of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University, Gastroenterology &amp; Hepatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Center for Liver Disease and Transplantation</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northest Clinical Research Center, LLC.</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center Investigation Drug Service</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of SA</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Mary's Immaculate Hospital</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary Liver Unit</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Centre for Liver Disease</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient Clinic of Internal Medicine</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ifi-Studien und Projekte GmbH, An der Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Internal Medicine - Medical School of Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre of the Johannes Guttenberg-University</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Giessen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitatsklinik Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PBC</keyword>
  <keyword>Primary Biliary Cholangitis (PBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seladelpar</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

